Hyundai Bioscience Co., Ltd. (KOSDAQ:048410)

South Korea · Delayed Price · Currency is KRW

6,390.00

-190.00 (-2.89%)

Sep 1, 2026, 3:30 PM KST

Hyundai Bioscience Financials Overview

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	3,321	3,517	15,050	9,481	7,852	9,241
Revenue Growth	77.96%	-76.63%	58.73%	20.76%	-15.04%	-26.14%
Gross Profit	-250.63	-1.69	11,792	4,992	2,712	3,229
Operating Income	-19,285	-18,161	833.79	-9,804	-26,311	-9,289
Net Income	-28,609	-22,128	-6,930	-14,499	-15,807	-20,051
Earnings Per Share	-297.67	-235.37	-87.56	-182.50	-201.00	-271.58
EPS Growth	-	-	-	-	-	-

Revenue by Geography

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
South Korea	3,021	3,378	9,815	284.5	3,964	8,128
Overseas	300.1	139.04	5,235	9,197	3,887	1,113
Total	3,321	3,517	15,050	9,481	7,852	9,241

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Investments	41,835	40,077	3,657	11,812	18,732	22,199
Total Debt	22,055	17,784	26,593	5,547	6,249	15,488
Net Cash (Debt)	19,781	22,293	-22,937	6,265	12,483	6,712
Net Cash Growth	-38.54%	-	-	-49.81%	86.00%	-
Net Cash Per Share	205.82	237.11	-288.02	78.76	158.55	90.90

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Cash Flow	-16,503	-17,050	2,257	-6,008	-16,544	-538.48
Capital Expenditures	-1,013	-1,194	-169.57	-539.7	-1,544	-3,747
Free Cash Flow	-17,516	-18,244	2,087	-6,548	-18,087	-4,285
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Gross Margin	-7.55%	-0.05%	78.35%	52.65%	34.53%	34.95%
Operating Margin	-580.74%	-516.32%	5.54%	-103.40%	-335.10%	-100.52%
Pretax Margin	-741.37%	-628.44%	-45.76%	-152.91%	-211.58%	-214.33%
Profit Margin	-861.51%	-629.12%	-46.04%	-152.92%	-201.33%	-216.97%
FCF Margin	-527.47%	-518.69%	13.87%	-69.06%	-230.36%	-46.37%

Valuation

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '26 Sep 1, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
P/FCF Ratio	-	-	269.15	-	-	-
PS Ratio	191.22	135.57	37.33	109.58	138.48	105.62